SkylineDx presents landmark findings from the largest prospective multicenter melanoma GEP trial at SSO 2025

SkylineDx Netherlands United States of America California New Jersey

Merlin CP-GEP test delivers high clinical utility – Study prospectively confirms precise risk stratification, optimizing SLNB referral recommendations.High clinical impact in subgroups – Merlin Low Risk patients show high negative predictive value (NPV), while Merlin High Risk patients exceed SLNB recommendation thresholds. and www.merlinmelanomatest.com. The test has been launched in the United States and Europe as Merlin test. SkylineDx collaborates with diagnostic service providers globally to bring this test to market and increase patient access. 

About SkylineDx
SkylineDx is a biotechnology company focused on research & development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predicting a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. SkylineDx is headquartered in Rotterdam. the Netherlands, complemented by a U.S. base of operations and a CAP/CLIA certified laboratory in San Diego California, USA. To learn more about SkylineDx, please visit www.skylinedx.com.

Footnotes:

1. T. Hieken et. al. Prospective multicenter evaluation (MERLIN_001 trial, NCT04759781) of a clinicopathologic and gene expression profile test to predict sentinel node status in T1-T3 cN0 melanoma SSO-2025-Heiken.pdf

 

View original content:https://www.prnewswire.co.uk/news-releases/skylinedx-presents-landmark-findings-from-the-largest-prospective-multicenter-melanoma-gep-trial-at-sso-2025-302414215.html